體外毒理學測試市場－全球產業規模、佔有率、趨勢、機會和預測，按技術、應用、方法、最終用戶、地區和競爭細分，2020 年至 2030 年

2024年全球體外毒理學測試市場規模為182.3億美元，預計2030年將達到328.8億美元，複合年成長率為10.29%。體外毒理學測試是評估各種物質對生物體外系統潛在毒性作用的科學過程，通常在實驗室環境下進行。 「體外」一詞在拉丁語中意為“在玻璃中”，指的是受控環境（例如試管、培養皿或其他人工系統）中進行的實驗，而不是在整個生物體內（體內）進行的實驗。這些測試用於評估化學物質、藥物、化妝品、消費品和其他物質的安全性，而不會使動物或人類受到潛在的有害影響。這些測試為了解物質在細胞、分子和生化層面的潛在風險和影響提供了寶貴的見解。體外測試也常用於篩選和確定物質的優先順序，以便在動物模型或臨床試驗中進一步測試。體外毒理學測試相較於傳統動物測試具有許多優勢，包括更符合倫理規範、更低成本和更短時間，以及高通量篩選的潛力。然而，它也有局限性，例如無法完全複製整個生物體的複雜性，以及體外系統和活體生物體之間的反應可能存在差異。體外毒理學測試可根據細胞培養試驗、酵素試驗、基因毒性試驗、細胞毒性試驗和高通量篩選 (HTS) 體外毒理學測試進行分類。

關鍵市場促進因素

對新藥和化學品安全評估的需求不斷成長

主要市場挑戰

生物系統的複雜性

主要市場趨勢

個人化醫療應用

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球體外毒理學測試市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依技術分類（細胞培養技術、高通量技術、分子影像、組學技術）
  • 依應用（全身毒理學、皮膚毒性、內分泌干擾、眼部毒性、其他）
  • 依方法（細胞測定、生化測定、電腦模擬、體外）
  • 按最終用戶（製藥業、化妝品和家用產品、學術機構和研究實驗室、診斷、化學工業、食品工業）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美體外毒理學測試市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲體外毒理學測試市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太體外毒理學檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲體外毒理學測試市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲體外毒理學測試市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Charles River Laboratories International, Inc.
• SGS SA
• Merck KGaA
• Eurofins Scientific
• Abbott Laboratories
• Laboratory Corporation of America Holdings
• Evotec SE
• Thermo Fisher Scientific, Inc.
• Quest Diagnostics Incorporated
• Agilent Technolgies, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

Global In-vitro Toxicology Testing Market was valued at USD 18.23 billion in 2024 and is expected to reach USD 32.88 billion in the forecast period with a CAGR of 10.29% through 2030. In-vitro Toxicology Testing are the scientific process of evaluating the potential toxic effects of various substances on biological systems outside of a living organism, typically in a laboratory setting. The term "in vitro" is Latin for "in glass," and it signifies experiments conducted in a controlled environment such as test tubes, culture dishes, or other artificial systems rather than in a whole living organism (in vivo). They are utilized to assess the safety of chemicals, drugs, cosmetics, consumer products, and other substances without subjecting animals or humans to potentially harmful effects. These tests provide valuable insights into the potential risks and effects of substances on cellular, molecular, and biochemical levels. In-vitro testing is also often used to screen and prioritize substances for further testing in animal models or clinical trials. In-vitro toxicology testing has several advantages over traditional animal testing, including ethical considerations, reduced cost and time, and potential for high-throughput screening. However, it also has limitations, such as the inability to fully replicate the complexity of whole organisms and potential differences in responses between in-vitro systems and living organisms. In-vitro Toxicology Testing can be categorized based on cell culture assays, Enzyme Assays, Genotoxicity Assays, Cytotoxicity Assays and High-Throughput Screening (HTS) In-vitro Toxicology Testing.

Key Market Drivers

Rising Demand For Safety Assessment Of New Drugs And Chemicals

The rising demand for safety assessment of new drugs and chemicals is significantly accelerating the adoption of in-vitro toxicology testing across various sectors. According to the U.S. FDA, nearly 70% of investigational new drug (IND) applications rely on non-animal methods, including in-vitro assays, during early screening phases. This underscores a growing trust in laboratory-based models for initial safety profiling. Additionally, a 2023 study published in Nature Reviews Drug Discovery highlighted that over 60% of pharmaceutical companies are now incorporating high-throughput in-vitro assays as part of their standard safety assessment protocols, reflecting a broader industry shift toward more predictive, cost-efficient, and ethically sound testing methodologies.

Beyond regulatory mandates, the ability of in-vitro toxicology testing to screen large chemical libraries in parallel using techniques such as high-content imaging and omics technologies has streamlined the early decision-making process in drug development. These tests reduce time-to-market and improve the success rate by identifying cytotoxic, genotoxic, or hepatotoxic risks before clinical trials. Moreover, the integration of human-relevant cell lines and organotypic cultures provides more accurate data on human biological responses, thereby improving the reliability of risk assessments. As precision medicine and chemical safety continue to be prioritized, in-vitro testing is becoming indispensable for safer and more efficient innovation.

The growing complexity and volume of new chemical entities (NCEs) entering research pipelines have also bolstered the importance of in-vitro toxicology testing. As chemical and pharmaceutical industries aim to bring safer products to market faster, in-vitro models help narrow down potential leads by providing critical toxicological profiles early in the development stage. Technologies such as microfluidic "organ-on-chip" platforms are being increasingly integrated to mimic human physiological responses more accurately, allowing researchers to predict organ-specific toxicity with higher precision. This technological advancement has empowered companies to make go/no-go decisions much earlier, saving significant R&D resources and improving product safety outcomes.

Key Market Challenges

Complexity of Biological Systems

The complexity of biological systems poses significant challenges to the global in-vitro toxicity testing market. While in-vitro methods offer numerous advantages, accurately replicating the intricate interactions and dynamic processes that occur within living organisms is a complex endeavor. The challenges arising from biological complexity impact the predictive accuracy, relevance, and applicability of in-vitro toxicity testing. In-vitro models often focus on individual cell types or simplified tissues, which fail to capture the interactions between different organs, tissues, and cell types that occur in the whole organism. This limitation reduces the ability to predict systemic effects and complex physiological responses. Cells in the body interact within a specific microenvironment, including extracellular matrix, signaling molecules, and neighboring cells. Replicating these interactions in in-vitro models is challenging, potentially leading to altered cellular behavior and responses.

Additionally, the metabolic capacity of in-vitro systems often falls short compared to that of an entire organism. Many toxic effects arise from metabolites generated during the body's metabolic processes, particularly in the liver. Standard in-vitro models may not accurately reproduce these metabolic transformations, leading to an underestimation or misinterpretation of a substance's toxicity. For instance, hepatocyte cultures may not fully reflect the enzymatic activity of a functioning liver, which is crucial for assessing the safety of drugs and chemicals.

Another layer of complexity is introduced by individual genetic variability. Humans exhibit differences in gene expression, metabolism, and immune responses, all of which influence how substances are processed in the body. Most in-vitro systems use standardized cell lines that do not capture this inter-individual variability. This presents a limitation in predicting population-wide safety outcomes and personalizing risk assessments. As a result, despite advances in 3D cultures and organ-on-chip technologies, translating in-vitro findings to real-world human scenarios remains a significant hurdle for researchers and regulatory bodies alike.

Key Market Trends

Personalized Medicine Applications

Personalized medicine applications represent a significant trend in the global in-vitro toxicity testing market. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, including their genetic makeup, lifestyle, and environmental factors. In the context of in-vitro toxicity testing, personalized medicine applications involve assessing how an individual's unique genetic and physiological characteristics influence their response to potential toxicants. In-vitro toxicity testing can be used to evaluate how a patient's specific genetic and molecular profile influences their susceptibility to adverse effects from chemicals and drugs. This approach enables more accurate and personalized risk assessments, helping to identify individuals who may be particularly sensitive to certain substances. By using patient-derived cells or tissues, researchers can conduct in-vitro toxicity testing to predict how an individual's body might respond to a particular compound. This information can guide treatment decisions and drug choices to maximize efficacy and minimize risks for each patient. In-vitro toxicity testing can help identify biomarkers or specific molecular indicators that signal potential toxic responses in certain individuals. These biomarkers can be used to monitor and predict toxicity in real-time during treatment. In-vitro toxicity testing can play a crucial role in identifying compounds that may lead to adverse reactions in specific patient populations. By selecting safer alternatives based on personalized testing, the risk of adverse effects can be significantly reduced.

Key Market Players

• Charles River Laboratories International, Inc.
• SGS S.A.
• Merck KGaA
• Eurofins Scientific
• Abbott Laboratories
• Laboratory Corporation of America Holdings
• Evotec S.E.
• Thermo Fisher Scientific, Inc.
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.

Report Scope:

In this report, the Global In-vitro Toxicology Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In-vitro Toxicology Testing Market, By Technology:

• Cell Culture Technology
• High Throughput Technology
• Molecular Imaging
• OMICS Technology

In-vitro Toxicology Testing Market, By Application:

• Systemic Toxicology
• Dermal Toxicity
• Endocrine Disruption
• Occular Toxicity
• Others

In-vitro Toxicology Testing Market, By Method:

• Cellular Assay
• Biochemical Assay
• In-silico
• Ex-vivo

In-vitro Toxicology Testing Market, By End User:

• Pharmaceutical Industry
• Cosmetics & Household Products
• Academic Institutes & Research Laboratories
• Diagnostics
• Chemicals Industry
• Food Industry

In-vitro Toxicology Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In-vitro Toxicology Testing Market.

Available Customizations:

Global In-vitro Toxicology Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In-vitro Toxicology Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Cell Culture Technology, High Throughput Technology, Molecular Imaging, OMICS Technology)
  • 5.2.2. By Application (Systemic Toxicology, Dermal Toxicity, Endocrine Disruption, Occular Toxicity, Others)
  • 5.2.3. By Method (Cellular Assay, Biochemical Assay, In-Silico, Ex-Vivo)
  • 5.2.4. By End-User (Pharmaceutical Industry, Cosmetics & Household Products, Academic Institutes & Research Laboratories, Diagnostics, Chemicals Industry, Food Industry)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America In-vitro Toxicology Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Method
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States In-vitro Toxicology Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Method
      • 6.3.1.2.4. By End-User
  • 6.3.2. Mexico In-vitro Toxicology Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Method
      • 6.3.2.2.4. By End-User
  • 6.3.3. Canada In-vitro Toxicology Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Method
      • 6.3.3.2.4. By End-User

7. Europe In-vitro Toxicology Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Method
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France In-vitro Toxicology Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Method
      • 7.3.1.2.4. By End-User
  • 7.3.2. Germany In-vitro Toxicology Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Method
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom In-vitro Toxicology Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Method
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy In-vitro Toxicology Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Method
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain In-vitro Toxicology Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Method
      • 7.3.5.2.4. By End-User

8. Asia-Pacific In-vitro Toxicology Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Method
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China In-vitro Toxicology Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Method
      • 8.3.1.2.4. By End-User
  • 8.3.2. India In-vitro Toxicology Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Method
      • 8.3.2.2.4. By End-User
  • 8.3.3. South Korea In-vitro Toxicology Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Method
      • 8.3.3.2.4. By End-User
  • 8.3.4. Japan In-vitro Toxicology Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Method
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia In-vitro Toxicology Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Method
      • 8.3.5.2.4. By End-User

9. South America In-vitro Toxicology Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Method
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil In-vitro Toxicology Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Method
      • 9.3.1.2.4. By End-User
  • 9.3.2. Argentina In-vitro Toxicology Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Method
      • 9.3.2.2.4. By End-User
  • 9.3.3. Colombia In-vitro Toxicology Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Method
      • 9.3.3.2.4. By End-User

10. Middle East and Africa In-vitro Toxicology Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Method
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa In-vitro Toxicology Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Method
      • 10.3.1.2.4. By End-User
  • 10.3.2. Saudi Arabia In-vitro Toxicology Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Method
      • 10.3.2.2.4. By End-User
  • 10.3.3. UAE In-vitro Toxicology Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Method
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Charles River Laboratories International, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. SGS S.A.
• 15.3. Merck KGaA
• 15.4. Eurofins Scientific
• 15.5. Abbott Laboratories
• 15.6. Laboratory Corporation of America Holdings
• 15.7. Evotec S.E.
• 15.8. Thermo Fisher Scientific, Inc.
• 15.9. Quest Diagnostics Incorporated
• 15.10. Agilent Technolgies, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer